Intersection · Compounds × needs a source
Compounds topics tagged needs a source
Topics in Compounds carrying the tag needs a source. A claim in this topic has been challenged and not yet supported.
50 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics…
|
+47 | 53 | 6.9k | 2h |
|
Reading a rodent study on a secretagogue without over-extrapolating — the long version
Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about Reading a rodent study,…
|
+59 | 66 | 30k | 4h |
|
Stability of BPC-157 in solution: what has been measured — one year on
On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. A narrow question about Stability of BPC-157, deliberately narrow,…
|
+84 | 98 | 7.8k | 18h |
|
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. What changes if the standard account of…
|
+7 | 11 | 31k | 19h |
|
Publication patterns in the BPC-157 literature, examined
Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. Putting the numbers in the first post, because a question about…
|
+40 | 45 | 3.4k | 21h |
|
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
+117 | 123 | 5.6k | 22h |
|
What would change my mind about repair peptides: a specific answer
What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Documentation question rather than a pharmacological…
|
+26 | 30 | 1.1k | 23h |
|
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I would like to…
|
+6 | 10 | 3.1k | 1d |
|
Why the absence of controlled human data on BPC-157 matters more than people admit
Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to know what people…
|
+60 | 66 | 16k | 1d |
|
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…
|
+72 | 81 | 44k | 1d |
|
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. What changes if the standard account of catalogue breadth is wrong?…
|
2 | 38k | 2d | |
|
Evidence quality in the secretagogue literature: an honest assessment
Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin evidence quality…
|
2 | 25k | 9d | |
|
Secretagogues and glucose tolerance: the mechanistic concern
On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion. Secretagogues and glucose tolerance, and specifically the version of it that…
|
+64 | 70 | 52k | 17d |
|
Why this subcategory is stricter about sourcing than most
Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most A comparison question rather than a question about one compound. Two things in the same…
|
+48 | 52 | 617 | 21d |
|
Naming conventions for research peptides and the confusion they cause
Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. I was wrong about naming conventions for research…
|
+21 | 25 | 4.9k | 22d |
|
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Something about stability of BPC-157 does not reconcile and I would like a second…
|
2 | 805 | 30d | |
|
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. The question about Analytical…
|
+28 | 33 | 1.6k | 1mo |
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. A follow-up question about Evidence quality that I did not know to…
|
+20 | 24 | 18k | 4mo |
|
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. IGF-1, and specifically the version of it that the documentation does not…
|
+5 | 9 | 35k | 4mo |
|
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin oral versus injected administration claims…
|
+20 | 24 | 47k | 4mo |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…
|
+35 | 39 | 688 | 5mo |
|
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Reading back through what has been written here about AOD-9604, three…
|
+40 | 44 | 2.8k | 6mo |
|
About the Other compounds category
Anything not covered by a dedicated subcategory, including research-use-only material with no human data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+8 | 12 | 51k | 7mo |
|
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…
|
+100 | 108 | 1.3k | 8mo |
|
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+86 | 97 | 62k | 8mo |
|
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Asking about Research-use-only status directly, because I…
|
2 | 309 | 9mo | |
|
Compounds this community declines to help with, and why
Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a compound without…
|
+81 | 87 | 35k | 10mo |
|
Why catalogue breadth is not evidence of anything — what changed since
Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since What changes if the standard account of catalogue breadth is wrong? I ask…
|
+62 | 66 | 26k | 10mo |
|
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. Reading a rodent study, and specifically the version…
|
+50 | 54 | 32k | 10mo |
|
BPC-157: what the rodent literature actually shows, and what it does not
BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I would like to know what people here actually do about BPC-157,…
|
+44 | 48 | 3k | 10mo |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →